(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Lightning on Jupiter could be up to 1 million times stronger than on Earth - 2Gym tied to outbreak of obscure disease that spreads through mist
- 3Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- 4NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- 56 Modest and Strong Tire Brands
- SF Chinatown's historic Empress of China building being revived into cultural campus
- Smoking rate among US adults drops to record low as vape use rises, CDC report finds
- Two Israeli infants among wounded by shrapnel in overnight Iranian missile barrage
- Cocoa Prices Settle Lower on Expectations of Adequate Supplies
- Fireball sightings are surging across the US — here's what's really going on
- She loves to give experiences. He goes for sentimental gifts. They ask an expert: What is the perfect holiday present?
- IDF strikes Tehran command centers, weapon production sites
- Worldwide Objections Ideal For A Golf Outing
- Brazil's former President Jair Bolsonaro seeks house arrest for prison time citing health issues
